SYROS PHARMACEUTICALS INC (SYRS)
US87184Q2066 - Common Stock
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ: SYRS). Such...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ: SYRS). Such...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ: SYRS). Such...
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ: SYRS). Such...
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged
/PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Syros Pharmaceuticals,...
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ: SYRS). Such...
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged
/PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Syros Pharmaceuticals,...
SYRS Investors Have Opportunity to Join Syros Pharmaceuticals, Inc. Securities Fraud Investigation with the Schall Law Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ: SYRS). Such...
Why Is Syros Pharmaceuticals (SYRS) Stock Down 62% Today?
Syros Pharmaceuticals stock is down on Tuesday as SYRS investors react to the company discontinuing enrollment for a clinical trial.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers for Tuesday as we check out all of the hottest news moving shares this morning.
Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial
Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update
Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
SYRS Stock Earnings: Syros Pharmaceuticals Beats EPS for Q1 2024
SYRS stock results show that Syros Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Syros to Participate in Upcoming Investor Conferences
Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
